Neurology

Links Between Long-Term Insomnia, Thinking Skills Over Time, Brain Amyloid Levels, and White Matter Changes in Older Adults with Normal Thinking

Updated

Abstract

Chronic insomnia is associated with a 40% increased risk of cognitive impairment in older adults.

  • Insomnia may lead to a faster decline in global cognitive scores at a rate of 0.011 points per year.
  • Insomnia with reduced sleep is linked to worse baseline cognitive performance and increased white matter hyperintensities.
  • Higher amyloid-PET levels are associated with insomnia and reduced sleep, suggesting poorer brain health.
  • Participants with insomnia who sleep more than usual may experience lower white matter hyperintensity burdens.
  • Hypnotic use in insomnia patients does not appear to influence cognitive scores or the risk of cognitive impairment.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

D.Z. Carvalho was supported by the NIA/NIH. B.P. Kolla has no relevant disclosures. S.J. McCarter was supported by NIH and the American Academy of Sleep Medicine Foundation; and has served as an investigator for clinical trials sponsored by Cognition Therapeutics and Cervomed but does not receive any personal compensation. E.K. St. Louis has received research support from the Mayo Clinic CCaTS, NIH, the Michael J. Fox Foundation, and Sunovion, Inc. M.M. Machulda was supported by the NIA/NIH. S.A. Przybelski and A.J. Fought have no relevant disclosures. V.J. Lowe has served as a consultant for Bayer Schering Pharma, Piramal Life Sciences, Life Molecular Imaging, Eisai Inc., Eli Lilly, AVID Radiopharmaceuticals, and Merck Research; and received research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals, and the NIH. V.K. Somers was supported by the NIH; has served as a consultant for Lilly, Apnimed, Jazz Pharmaceuticals, and Axsome; and is on the scientific advisory board for Sleep Number Corporation. B.F. Boeve has served as an investigator for clinical trials sponsored by Alector, Biogen, Cognition Therapeutics, EIP Pharma, and Transposon; and served on the scientific advisory board of the Tau Consortium. R.C. Petersen has served as a consultant for Roche Inc., Merck Inc., Genentech Inc., Eli Lilly and Co., Eisai Inc., Novartis, and Novo Nordisk; and received royalties from Oxford University Press for the publication of Mild Cognitive Impairment and UpToDate. C.R. Jack Jr. was supported by the NIA/NIH. J. Graff-Redford was supported by the NIH; is on the drug safety medical board for the National Institute of Neurological Disorders and Stroke; is the site PI for a clinical trial funded by Eisai and Cognition Therapeutics; and is an associate editor for JAMA Neurology . A.W. Varga has served as a consultant for Jazz Pharmaceuticals and Axsome Therapeutics; and was supported by R01 AG066870 and R01 AG080609. P. Vemuri was supported by the NIH. Go to Neurology.org/N for full disclosures.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free